Temple University
temple.eduTotal trials
223
Active
30
Phase 3
11
Total enrollment
39,946
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Clavulanic Acid Only Product | — | — | — | — | — | 1 |
Next readouts
- 2024-07
Top conditions
- Obesity18
- Overweight6
- Hypertension5
- Diabetes Mellitus5
- Chronic Obstructive Pulmonary Disease5
- Gastroparesis4
- Anxiety4
- Bipolar Disorder4
Frequently asked questions about Temple University
- How many clinical trials does Temple University have on ClinicalTrials.gov?
- Temple University is listed as the lead sponsor on 223 clinical trials in ClinicalTrials.gov, 30 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Temple University's trials are in Phase 3?
- 11 of Temple University's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does Temple University focus on?
- Temple University's most-studied conditions on ClinicalTrials.gov are Obesity, Overweight, Hypertension, Diabetes Mellitus, Chronic Obstructive Pulmonary Disease.
- When are Temple University's next clinical trial readouts?
- Temple University has 1 upcoming primary-completion readout tracked here; the soonest is “Clavulanic Acid for the Treatment of Cocaine Use Disorder”, expected around 2024-07.